JSAM
AXSM icon

J. Safra Asset Management’s Axsome Therapeutics AXSM Stock Holding History

J. Safra Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.32K Sell
34
-7
-17% -$1.52K ﹤0.01% 424
2026
Q1 		$6.93K Buy
+41
New +$7.08K ﹤0.01% 413

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

J. Safra Asset Management's AXSM Position: Q2 2026 in Review

J. Safra Asset Management reduced its Axsome Therapeutics (AXSM) stake by 17% in Q2 2026, selling an estimated $1.52K and leaving 34 shares worth $8.32K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

J. Safra Asset Management first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • J. Safra Asset Management held 34 shares of Axsome Therapeutics worth $8.32K as of Q2 2026.
  • J. Safra Asset Management sold 7 Axsome Therapeutics shares in Q2 2026, an estimated $1.52K.
  • Axsome Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #424 holding.
  • J. Safra Asset Management first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.